Journal article
OA-14 Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM): Phase I Dose-Expansion Results from the CAMMA 1 Study
Authors
Mian HS; Riley CH; Popat R; Grosicki S; Lavi N; Harrison S; Mihalyova J; Kim K; Trudel S; Szarejko M
Journal
Clinical Lymphoma Myeloma & Leukemia, Vol. 25, ,
Publisher
Elsevier
Publication Date
September 1, 2025
DOI
10.1016/s2152-2650(25)03418-4
ISSN
2152-2650